secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001193125-25-174540
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Pharma reports Q2 2025 revenue of $146.6M (+19.4% YoY); GAAP net income $52.1M
--------------------------------------------------------------------------------

- FIRDAPSE Q2 net revenue $84.8M (+9.7% YoY); first-half 2025 net revenue $168.6M (+16.9% YoY).
- AGAMREE Q2 net revenue $27.4M (+212.9% YoY); first-half net revenue $49.4M (+398.0% YoY).
- FYCOMPA Q2 net revenue $34.3M (-6.0% YoY due to generic entry post LOE).
- Non-GAAP diluted EPS $0.68, up from $0.56 in Q2 2024; cash $652.8M, no funded debt.
- Reaffirmed FY2025 total revenue guidance of $545M to $565M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525174540/0001193125-25-174540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525174540/d941750d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-174540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer